sdz 220-581 has been researched along with haloperidol in 1 studies
Studies (sdz 220-581) | Trials (sdz 220-581) | Recent Studies (post-2010) (sdz 220-581) | Studies (haloperidol) | Trials (haloperidol) | Recent Studies (post-2010) (haloperidol) |
---|---|---|---|---|---|
11 | 0 | 5 | 20,330 | 1,753 | 3,294 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
McAllister, KH | 1 |
1 other study(ies) available for sdz 220-581 and haloperidol
Article | Year |
---|---|
The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
Topics: Animals; Antipsychotic Agents; Binding, Competitive; Biphenyl Compounds; Catalepsy; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Haloperidol; Male; Molecular Structure; Neuroprotective Agents; Propionates; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Statistics, Nonparametric; Structure-Activity Relationship | 1996 |